Sosei Group. has filed a patent for novel compounds and their salts, which can be used in treating disorders associated with Glucagon-like peptide (GLP) receptors. The compounds have a specific chemical formula and can be substituted with various groups. The patent also covers different sequences and groups within the compounds. GlobalData’s report on Sosei Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sosei Group, was a key innovation area identified from patents. Sosei Group's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Compound for treating disorders associated with glp receptors
A recently filed patent (Publication Number: US20230295260A1) describes a compound with a specific chemical sequence and its various applications in the field of gastrointestinal and metabolic diseases. The compound is represented by a formula (1) and consists of different components such as Q, Rq, n, R1, R2, W, X, Y, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, LysR, and the AA9 C-terminus. These components have specific variations and substitutions that contribute to the compound's structure and function.
The compound can have different variations and substitutions for Q, which can be phenyl or a monocyclic heteroaryl ring. The compound can also have a value of n ranging from 1 to 3. R1 and R2, which are attached to the carbon atom, can be independently selected from hydrogen or a C1-6 alkyl group. In some cases, both R1 and R2 can be methyl. R3 can represent -CH2tetrazolyl, and R4a can be hydrogen or methyl. R4b can be a benzyl group optionally substituted with fluorine. R5a can be hydrogen or methyl, and R5b can be isobutyl or -CH2CONH2. R6a can be hydrogen or methyl, and R6b can be isobutyl or sec-butyl. R7a can be hydrogen or methyl, and R7b can be benzyl or -CH2COOH. LysR, an N-substituted Lysine residue, can have different variations and substitutions. The AA9 C-terminus can be a carboxyl group or a carboxamide group.
The compound described in the patent can be used in the treatment of various gastrointestinal and metabolic diseases, including but not limited to malabsorption disorders, inflammatory bowel disorders, obesity, diabetes, and autoimmune diseases. It can also be used to improve mucosal barrier function, promote intestinal recovery, and enhance nutritional status. The compound can be formulated into a pharmaceutical composition with a pharmaceutically acceptable excipient. The patent also mentions specific disorders such as Tufting enteropathy, which can be treated using the compound.
Overall, the patent describes a compound with a specific chemical sequence and its potential applications in the field of gastrointestinal and metabolic diseases. The compound's variations and substitutions allow for different functionalities and therapeutic uses. The patent provides a comprehensive overview of the compound's structure, variations, and potential applications, making it a valuable resource for researchers and pharmaceutical companies in the field.
To know more about GlobalData’s detailed insights on Sosei Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
